AU2016279997B2 - Dimethyl fumarate particles and pharmaceutical compositions thereof - Google Patents

Dimethyl fumarate particles and pharmaceutical compositions thereof Download PDF

Info

Publication number
AU2016279997B2
AU2016279997B2 AU2016279997A AU2016279997A AU2016279997B2 AU 2016279997 B2 AU2016279997 B2 AU 2016279997B2 AU 2016279997 A AU2016279997 A AU 2016279997A AU 2016279997 A AU2016279997 A AU 2016279997A AU 2016279997 B2 AU2016279997 B2 AU 2016279997B2
Authority
AU
Australia
Prior art keywords
dmf
particles
dosage form
hours
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2016279997A
Other languages
English (en)
Other versions
AU2016279997A1 (en
Inventor
Pierre BOULAS
Erwin IRDAM
Shyam B. Karki
William F. Kiesman
Cheuk-Yui LEUNG
Yiqing Lin
Andrea TREMENTOZZI
Peter ZAWANEH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen MA Inc filed Critical Biogen MA Inc
Publication of AU2016279997A1 publication Critical patent/AU2016279997A1/en
Application granted granted Critical
Publication of AU2016279997B2 publication Critical patent/AU2016279997B2/en
Priority to AU2022200155A priority Critical patent/AU2022200155A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2016279997A 2015-06-17 2016-06-15 Dimethyl fumarate particles and pharmaceutical compositions thereof Ceased AU2016279997B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2022200155A AU2022200155A1 (en) 2015-06-17 2022-01-12 Dimethyl fumarate particles and pharmaceutical compositions thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562181061P 2015-06-17 2015-06-17
US62/181,061 2015-06-17
PCT/US2016/037486 WO2016205270A1 (en) 2015-06-17 2016-06-15 Dimethyl fumarate particles and pharmaceutical compositions thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022200155A Division AU2022200155A1 (en) 2015-06-17 2022-01-12 Dimethyl fumarate particles and pharmaceutical compositions thereof

Publications (2)

Publication Number Publication Date
AU2016279997A1 AU2016279997A1 (en) 2018-01-18
AU2016279997B2 true AU2016279997B2 (en) 2021-10-21

Family

ID=56292916

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016279997A Ceased AU2016279997B2 (en) 2015-06-17 2016-06-15 Dimethyl fumarate particles and pharmaceutical compositions thereof
AU2022200155A Abandoned AU2022200155A1 (en) 2015-06-17 2022-01-12 Dimethyl fumarate particles and pharmaceutical compositions thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2022200155A Abandoned AU2022200155A1 (en) 2015-06-17 2022-01-12 Dimethyl fumarate particles and pharmaceutical compositions thereof

Country Status (13)

Country Link
US (2) US11291642B2 (enExample)
EP (1) EP3310341A1 (enExample)
JP (2) JP2018517735A (enExample)
KR (1) KR20180018711A (enExample)
CN (1) CN107920997A (enExample)
AU (2) AU2016279997B2 (enExample)
CA (1) CA2989581A1 (enExample)
EA (1) EA201890068A1 (enExample)
HK (1) HK1254054A1 (enExample)
IL (1) IL256296A (enExample)
MA (1) MA42196A (enExample)
MX (1) MX387092B (enExample)
WO (1) WO2016205270A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016344673A1 (en) * 2015-10-28 2018-05-17 Sun Pharmaceutical Industries Limited Pharmaceutical compositions of dimethyl fumarate
CA3013472A1 (en) * 2016-02-11 2017-08-17 Biogen Ma Inc. Pharmaceutical bead formulations comprising dimethyl fumarate
CA3075720A1 (en) * 2017-10-02 2019-04-11 Novartis Ag Method for preparing a pharmaceutical product
WO2019194826A1 (en) 2018-04-06 2019-10-10 Hewlett-Packard Development Company, L.P. Three-dimensional (3d) object printing based on build material permeability
US12098291B2 (en) * 2018-10-05 2024-09-24 Isp Investments Llc Smooth high solids film coating composition comprising water soluble cellulose ether, process for preparing the same and method of use thereof
TR201818293A2 (tr) * 2018-11-30 2020-06-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Di̇meti̇l fumarat i̇çeren geci̇kmeli̇ salim sağlayan kapsül
CN113365609A (zh) * 2019-01-31 2021-09-07 伊勒卓菲公司 颗粒形成和形态
CA3134186A1 (en) * 2019-03-20 2020-09-24 Lyndra Therapeutics, Inc. Coatings for gastric residence dosage forms
US12447130B2 (en) * 2019-03-20 2025-10-21 Lyndra Therapeutics, Inc. Capsules and capsule coatings for gastric residence dosage forms
CN116669715A (zh) * 2020-11-18 2023-08-29 Fb-Hrs有限责任公司 含有多非利特和美西律的组合物及其应用
CN116887866A (zh) 2020-12-03 2023-10-13 巴特尔纪念研究院 聚合物纳米颗粒和dna纳米结构组合物及用于非病毒递送的方法
JP2024516108A (ja) 2021-04-07 2024-04-12 バテル・メモリアル・インスティテュート 非ウイルス性担体を同定および使用するための迅速な設計、構築、試験、および学習技術
MX2023014395A (es) 2021-06-04 2023-12-15 Zim Laboratories Ltd Composiciones de liberacion retardada de dimetilfumarato.
US11590071B2 (en) * 2021-07-06 2023-02-28 King Abdulaziz University Injectable drug delivery implant composition and method of use thereof
WO2025072751A1 (en) 2023-09-29 2025-04-03 Battelle Memorial Institute Polymer nanoparticle compositions for in vivo expression of polypeptides
WO2025090498A1 (en) * 2023-10-23 2025-05-01 Isp Investments Llc Encapsulated medium chain fatty acid salts and oral solid dosage forms derived therefrom
US12441996B2 (en) 2023-12-08 2025-10-14 Battelle Memorial Institute Use of DNA origami nanostructures for molecular information based data storage systems
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010079222A1 (en) * 2009-01-09 2010-07-15 Forward Pharma A/S Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
WO2012170923A1 (en) * 2011-06-08 2012-12-13 Biogen Idec Ma Inc. Process for preparing high purity and crystalline dimethyl fumarate
WO2015042294A1 (en) * 2013-09-18 2015-03-26 Xenoport, Inc. Nanoparticle compositions of dimethyl fumarate
WO2015044853A2 (en) * 2013-09-25 2015-04-02 Glenmark Pharmaceuticals Limited; Glenmark Generics Limited Process for preparation of dimethyl fumarate
WO2015089420A1 (en) * 2013-12-13 2015-06-18 Biogen Idec Ma Inc. Controlled release dosage form for once daily administration of dimethyl fumarate
WO2015130998A1 (en) * 2014-02-28 2015-09-03 Banner Life Sciences Llc Controlled release enteric soft capsules of fumarate esters

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2725623A1 (fr) 1994-10-18 1996-04-19 Flamel Tech Sa Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
DE19853487A1 (de) 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
IL133196A0 (en) 1999-11-29 2001-03-19 Yissum Res Dev Co Gastroretentive controlled release pharmaceutical dosage forms
DE10101307A1 (de) * 2001-01-12 2002-08-01 Fumapharm Ag Muri Fumarsäurederivate als NF-kappaB-Inhibitor
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
SI2801354T1 (sl) * 2004-10-08 2017-07-31 Forward Pharma A/S Farmacevtske sestave z nadzorovanim sproščanjem, ki zajemajo ester fumarne kisline
HUE027282T2 (en) 2006-01-18 2016-11-28 Intec Pharma Ltd A method for preparing a dosing device for oral administration of the agent
US8771730B2 (en) * 2008-04-18 2014-07-08 Intec Pharma Ltd. Carbidopa/Levodopa gastroretentive drug delivery
JP2012514623A (ja) * 2009-01-09 2012-06-28 フォーワード・ファルマ・アクティーゼルスカブ １またはそれ以上のフマル酸エステルを含む医薬組成物
WO2013076216A1 (en) 2011-11-24 2013-05-30 Synthon Bv Controlled release particles comprising dimethyl fumarate
CN113244185A (zh) 2012-02-07 2021-08-13 比奥根玛公司 含有富马酸二甲酯的药物组合物

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010079222A1 (en) * 2009-01-09 2010-07-15 Forward Pharma A/S Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
WO2012170923A1 (en) * 2011-06-08 2012-12-13 Biogen Idec Ma Inc. Process for preparing high purity and crystalline dimethyl fumarate
WO2015042294A1 (en) * 2013-09-18 2015-03-26 Xenoport, Inc. Nanoparticle compositions of dimethyl fumarate
WO2015044853A2 (en) * 2013-09-25 2015-04-02 Glenmark Pharmaceuticals Limited; Glenmark Generics Limited Process for preparation of dimethyl fumarate
WO2015089420A1 (en) * 2013-12-13 2015-06-18 Biogen Idec Ma Inc. Controlled release dosage form for once daily administration of dimethyl fumarate
WO2015130998A1 (en) * 2014-02-28 2015-09-03 Banner Life Sciences Llc Controlled release enteric soft capsules of fumarate esters

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Aihc Pharma ET AL, Laboratory Services Bureau Veritas North America, (2015-06-03), http://www.pharmaforumpage.com/PharmaForumWP/wp-content/uploads/2015/06/DMFu-Challenges-_Pharmaforum2015_Petroka_Ballinger_Meiners_Hemp.pdf *

Also Published As

Publication number Publication date
AU2022200155A1 (en) 2022-02-10
MA42196A (fr) 2018-04-25
CA2989581A1 (en) 2016-12-22
IL256296A (en) 2018-02-28
EP3310341A1 (en) 2018-04-25
WO2016205270A8 (en) 2017-01-19
EA201890068A1 (ru) 2018-09-28
US20190070143A1 (en) 2019-03-07
WO2016205270A1 (en) 2016-12-22
MX387092B (es) 2025-03-19
AU2016279997A1 (en) 2018-01-18
KR20180018711A (ko) 2018-02-21
MX2017016509A (es) 2018-08-16
JP2018517735A (ja) 2018-07-05
JP2022042512A (ja) 2022-03-14
US11291642B2 (en) 2022-04-05
CN107920997A (zh) 2018-04-17
US20220362195A1 (en) 2022-11-17
HK1254054A1 (zh) 2019-07-12

Similar Documents

Publication Publication Date Title
US20220362195A1 (en) Dimethyl fumarate particles and pharmaceutical compositions thereof
US10172794B2 (en) Controlled release dosage form for once daily administration of dimethyl fumarate
US8277843B2 (en) Programmable buoyant delivery technology
JP5808670B2 (ja) 弱塩基性薬物を含む組成物及び徐放性剤形
CN109044981B (zh) 一种普瑞巴林胃漂浮型缓释片及其制备方法
US11090279B2 (en) Delayed release cysteamine bead formulation, and methods of making and using same
PL179910B1 (pl) Postac dawkowania o kontrolowanym uwalnianiu zawierajaca azytromycyne PL PL PL PL PL PL PL PL
WO1996019200A1 (en) Sustained-release granular preparation and process for producing the same
CN101862297A (zh) 一种非水溶性药物的缓释微丸、其缓释口腔崩解片及其制备方法
JP2005524654A (ja) ３８Ｎ／ｃｍ２以下の抗張力を持った核錠と軟質の核錠を保護する被膜を持った投薬物
EP1238662B1 (en) Method for manufacturing drug granules, the drug granules and pharmaceutical preparation containing the drug granules
TW200924737A (en) Galenical formulations of organic compounds
WO2012074042A1 (ja) ヒドロキシアルキルセルロース
ES2683366T3 (es) Dispersión molecular sólida de fesoterodina
CN101862305A (zh) 一种盐酸氨溴索缓释微丸及制备方法
WO2009101658A1 (ja) 時限放出製剤
WO2003070223A1 (en) Sustained release preparations and process for producing the same
CN1568954A (zh) 美沙拉嗪结肠定位释药微丸制剂及其制备方法
WO2014063596A1 (zh) 一种治疗糖尿病的口服制剂
Tamizharasi et al. Floating drug delivery system.
CN1729964B (zh) 一种具有膨胀核心的掩味微囊及制备方法
Kulkarni et al. Gastroretentive Drug Delivery Systems
Naveena et al. Preparation And Evaluation of Floating Microsphere J Clinical Case Studies and Review Reports. 1 (1): 1
KHARAT et al. Indian Journal of Novel Drug Delivery
Gupta Design and evaluation of pH sensitive multi-particulate systems for chronotherapeutic delivery of pioglitazone hydrochloride

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired